IP Library Granted Patent US 9,845,324
Granted Patent B2
US 9,845,324 · App. 15/049,613 · Granted Dec 19, 2017

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,845,324
App. No.
15/049,613
Granted
Dec 19, 2017
Kind
B2
Abstract

This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.

Claims (47)

1. A compound having formula (10)

or a pharmaceutically acceptable salt thereof;

wherein R 1 is selected from the group consisting of H, C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl wherein C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl are optionally substituted with C 1-4 alkyl, C 1-4 alkoxyl, hydroxyl, perhalogenated C 1-4 alkyl, or halogen, and

wherein R 2 is a substituted or an unsubstituted, heterocycloalkylalkyl.

2. The compound of claim 1 , wherein the substituted heterocycloalkylalkyl is a morpholinoalkyl or piperazinylalkyl group.

3. A compound having formula (10)

or a pharmaceutically acceptable salt thereof;

wherein R 1 is selected from the group consisting of H, C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl wherein C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl are optionally substituted with C 1-4 alkyl, C 1-4 alkoxyl, hydroxyl, perhalogenated C 1-4 alkyl, or halogen; and

wherein R 2 is a substituted or an unsubstituted heteroarylalkyl, and wherein the substituted heteroarylalkyl is a pyridylalkyl or isoxazolidinylalkyl group.

4. A compound having formula (40)

or a pharmaceutically acceptable salt thereof; wherein

wherein R 1 is selected from the group consisting of H, C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl wherein C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl are optionally substituted with C 1-4 alkyl, C 1-4 alkoxyl, hydroxyl, perhalogenated C 1-4 alkyl, or halogen; and

wherein R a1 , R a3 , and R a5 are each hydrogen; and

wherein R a2 and R a4 are fluorine.

5. A compound having formula (50)

or a pharmaceutically acceptable salt thereof; wherein

R 1 is selected from the group consisting of H, C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl wherein C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl are optionally substituted with C 1-4 alkyl C 1-4 alkoxyl, hydroxyl, perhalogenated C 1-4 alkyl, or halogen; and

wherein R a2 , R a4 , R a5 , are each hydrogen, R b is a fluorine and R a1 is a methyl.

6. A compound having formula (50)

or a pharmaceutically acceptable salt thereof; wherein

R 1 is selected from the group consisting of H, C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl wherein C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl are optionally substituted with C 1-4 alkyl, C 1-4 alkoxyl, hydroxyl, perhalogenated C 1-4 alkyl, or halogen; and

wherein R a1 , R a4 , R a5 , are each hydrogen, and wherein R b and R a2 are each selected from fluorine or chlorine.

7. A compound having formula (60)

or a pharmaceutically acceptable salt thereof;

wherein R 1 is selected from the group consisting of H, C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl wherein C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl are optionally substituted with C 1-4 alkyl, C 1-4 alkoxyl, hydroxyl, perhalogenated C 1-4 alkyl, or halogen.

8. A compound having formula (50)

or a pharmaceutically acceptable salt thereof; wherein

R 1 is selected from the group consisting of H, C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl wherein C 1-4 alkyl, C 1-4 alkylphenyl, C 1-4 alkylphenylketone, C 1-4 benzyl-piperazine, C 1-4 alkylthienyl, C 1-4 alkylpyridinyl, C 1-4 alkylisoxazolidinyl, C 1-4 alkylmorpholinyl, C 1-4 alkylthiazolyl, and C 1-4 alkylpyrazinyl are optionally substituted with C 1-4 alkyl, C 1-4 alkoxyl, hydroxyl, perhalogenated C 1-4 alkyl, or halogen; and

wherein R a1 , R a4 , R a5 , are each hydrogen, R b is Cl, and R a1 is Cl.

9. A composition comprising a salt of a compound of claim 6 .

10. The composition according to claim 9 , wherein the salt is a di-salt.

11. The composition according to claim 10 , wherein the di-salt is a hydrochloride di-salt.

12. A pharmaceutical composition comprising a compound according to claim 6 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

13. The compound of claim 6 , wherein R b and R a2 are each fluorine.

14. The compound of claim 7 , wherein R 1 is a benzyl.

15. A composition comprising a salt of a compound of claim 7 .

16. The composition according to claim 15 , wherein the salt is a di-salt.

17. The composition according to claim 16 , wherein the di-salt is a hydrochloride di-salt.

18. A pharmaceutical composition comprising a compound according to claim 7 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

19. A composition comprising a salt of a compound of claim 13 .

20. The composition according to claim 19 , wherein the salt is a di-salt.

21. The composition according to claim 20 , wherein the di-salt is a hydrochloride di-salt.

22. A pharmaceutical composition comprising a compound according to claim 13 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

23. A composition comprising a salt of a compound of claim 22 .

24. The composition according to claim 23 , wherein the salt is a di-salt.

25. The composition according to claim 24 , wherein the di-salt is a hydrochloride di-salt.

26. A pharmaceutical composition comprising a compound according to claim 13 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2017
From: POTTORF, RICHARD S.; NALLAGANCHU, BHASKARA RAO; OLSON, GARY; SUN, YANJUN
To: PROVID PHARMACEUTICALS INC.
Reel/Frame 041835/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2017
From: PROVID PHARMACEUTICALS INC.
To: ONCOCEUTICS, INC.
Reel/Frame 042146/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2016
From: STOGNIEW, MARTIN; ALLEN, JOSHUA E.
To: ONCOCEUTICS, INC.
Reel/Frame 040360/0549 →